SCHEMBL5547037

SCHEMBL5547037

NCCCN1CCOCC1.O=C(NCCCN1CCOCC1)c1c(O)c2ncc(Cc3ccc(F)cc3)cc2n(CCN2C(=O)c3ccccc3C2=O)c1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.45
NPSR1 Q6W5P4 2/20 0.45
MEN1 O00255 1/20 0.45
ALDH1A1 P00352 2/20 0.42
CNR2 P34972 7/20 0.42
CNR1 P21554 5/20 0.41
POLB P06746 1/20 0.41
KDM4E B2RXH2 2/20 0.41
LMNA P02545 1/20 0.41
GLA P06280 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
RECQL P46063 1/20 0.41
ATM Q13315 1/20 0.41
PIK3CA P42336 1/20 0.40
TP53 P04637 1/20 0.40
NPBWR1 P48145 1/20 0.40
MCHR1 Q99705 1/20 0.40
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5547346 0.93 CNR2 (0.47) ALDH1A1CNR2CNR1POLBHPGD
SCHEMBL5545314 0.90 ALDH1A1 (0.47) NPSR1ALDH1A1CNR2CNR1KDM4E
SCHEMBL5545729 0.86 CNR2 (0.49) CNR2CNR1HPGDPIK3CATSHR
SCHEMBL15163489 0.86 CNR2 (0.45) NPSR1ALDH1A1CNR2CNR1KDM4E
Hydrochloric Acid SCHEMBL5545865 0.85 CNR2 (0.45) NPSR1ALDH1A1CNR2CNR1KDM4E
SCHEMBL5540707 0.85 CNR2 (0.47) NPSR1ALDH1A1CNR2CNR1LMNA
SCHEMBL15163633 0.84 CNR2 (0.46) KMT2AMEN1ALDH1A1CNR2CNR1
SCHEMBL5538937 0.84 RXFP1 (0.42) KMT2AALDH1A1KDM4ELMNAGAA
SCHEMBL5541117 0.84 TSHR (0.47) KMT2ANPSR1MEN1ALDH1A1CNR2
SCHEMBL5540832 0.84 KDM4E (0.43) KMT2AMEN1POLBKDM4ETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225399-A1 HIV INTEGRASE INHIBITORS VIIV HEALTHCARE CO (US) 2015-08-13 US disclosed
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS SHIONOGI & CO., LTD. (JP) 2014-09-11 US disclosed
EP-1720856-B1 HIV INTEGRASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-08-14 EP disclosed
US-20070124152-A1 Hiv Integrase Inhibitors GLAXOSMITHKLINE LLC 2007-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS BCDIN3D, DUT, SAMHD1 KMT2A 502/4885NPSR1 4539/4885MEN1 4802/4885
US-20150225399-A1 HIV INTEGRASE INHIBITORS ING2, API5, SAMHD1 KMT2A 819/4885NPSR1 4734/4885MEN1 4837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.